{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kaplonek P"],"funding":["NICHD NIH HHS","NIAID NIH HHS","NCI NIH HHS"],"pagination":["eabm2311"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8995030"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(645)"],"pubmed_abstract":["The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-induced neutralizing antibodies, real-world vaccine efficacy has begun to show differences across the two approved mRNA platforms, BNT162b2 and mRNA-1273; these findings suggest that subtle variation in immune responses induced by the BNT162b2 and mRNA-1273 vaccines may confer differential protection. Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the postboost binding and functional capacity of humoral immune responses induced by the BNT162"],"journal":["Science translational medicine"],"pubmed_title":["mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions."],"pmcid":["PMC8995030"],"funding_grant_id":["R01 AI042790","U01 CA260476","K12 HD000849","R01 AI146785","75N93019C00052","R37 AI080289","U19 AI135995"],"pubmed_authors":["Fischinger S","Broge T","Musk ER","Lauffenburger DA","de St Aubin M","Barouch DH","Suscovich T","Amanat F","Cizmeci D","Menon AS","Dayal D","Alter G","Collier AR","Krammer F","Linde C","Rhee J","Mann C","Kaplonek P","Nilles EJ","Saphire EO"],"additional_accession":[]},"is_claimable":false,"name":"mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.","description":"The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-induced neutralizing antibodies, real-world vaccine efficacy has begun to show differences across the two approved mRNA platforms, BNT162b2 and mRNA-1273; these findings suggest that subtle variation in immune responses induced by the BNT162b2 and mRNA-1273 vaccines may confer differential protection. Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the postboost binding and functional capacity of humoral immune responses induced by the BNT162","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-21T17:35:12.613Z","creation":"2025-04-05T16:40:45.02Z"},"accession":"S-EPMC8995030","cross_references":{"pubmed":["35348368"],"doi":["10.1126/scitranslmed.abm2311"]}}